Track topics on Twitter Track topics that are important to you
Metastatic triple-negative breast cancer has one of the worst prognoses of all cancers. Its associated median overall survival of only 13 months has not changed for almost two decades despite many efforts to develop alternative approaches to chemotherapy, including targeting angiogenesis, DNA repair, and EGFR.1 Potential explanations are the very heterogeneous and unstable nature of this disease, together with the absence of known leading oncogenic drivers.1,2
Original Article: [Comment] Targeting PI3K/AKT pathway in triple-negative breast cancerNEXT ARTICLE
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...